NCT07639723

Aprepitant to Improve Same Day Discharge for TKA

Not Yet Recruiting
PHASE4Ages 18–90InterventionalPrevention
Endeavor Health
~350 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Aprepitant InjectionOndansetron (Zofran)DexamethasonePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
difference in the incidence of same-day discharges between two randomized groups of anti-emetic regimens for anesthesia care
Measured over patients will be followed from arrival for surgery to 7 days post operatively
PONV
1 sites across 1 states
Illinois1
  • Steven Greenberg, MD · PRINCIPAL_INVESTIGATOR · Endeavor Health

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Receiving primary, unilateral elective TKA with or without abductor canal block
Asa I-III
Age 18-90
Ability to receive ondansetron and dexamethasone
Ability to consent and complete surveys
English or Spanish speaking
Receiving regional anesthesia (epidural or spinal) for surgery

Exclusion

Allergy to any of the anti-emetics being administered
Current treatment of pimozide
Emergent surgery
Revision/ multiple revisions of TKA
Clinical suspicion of possible bowel obstruction
Need for general anesthesia
Pregnant/breast feeding
AST\> 2.5 x the upper limit of normal or ALT\> 2.5 x upper limit of normal, bilirubin\> 1.5x upper limit of normal
Need for opioid or benzodiazepine antagonists
Not planned for same day discharge
Enrollment in a different drug trial for TKA
Unable to consent in English or Spanish
  • difference in the incidence of same-day discharges between two randomized groups of anti-emetic regimens for anesthesia carepatients will be followed from arrival for surgery to 7 days post operatively

    difference in the incidence of same-day discharges between two randomized groups of anti-emetic regimens for anesthesia care. Subjects will be randomized to either the aprepitant group (administration of aprepitant, ondansetron, and dexamethasone) or control (ondansetron, dexamethasone, and placebo). PACU and ASU staff will collect real time data with regard to the primary and secondary reason for any hospital admission (PONV, Pain control, Rapid response team called, Vital sign abnormalities, Change in mental status, Other). Same day discharge will be defined by patients who are discharged from the hospital before 12 A.M day of surgery. We will use the validated simplified PONV Impact Scale that uses patient assessment of nausea and vomiting to identify clinically important PONV upon PACU and ASU discharge (a PONV impact scale score of greater than or equal to 5 defines clinically important PONV).